Creon 40,000 will not be available from June 2019
If you have been prescribed Creon, we would like to inform you that Mylan the marketing authorisation holder for Creon, has decided to voluntarily discontinue the manufacture and distribution of Creon 40,000 from June 2019. It’s important to note that this decision is not associated with any safety or efficacy findings.
Why have Mylan discontinued Creon 40,000?
Producing Creon 40,000 requires a different concentration of active enzymes to other doses. These enzymes have been decreasing over the last few years. Because of this Creon 40,000 has experienced frequent supply problems.
Will I still be able to take Creon?
Creon capsules are interchangeable, you will be able to use other doses to make up for the loss of 40,000. This will involve you needing to take more tablets, but the smaller doses are easier to swallow.
However, we advise that you speak with your healthcare professional regarding transferring to a different strength capsule to achieve the required dose.
Speaking to your doctor in plenty of time will mean your prescription is changed and ready for the discontinuation.
Mylan will have a limited quantity of Creon 40,000 available up to June 2019.
If you have any questions, please contact Mylan Medical Information: [email protected] or e-mail Pancreatic Cancer Action: [email protected]